|
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
|
Positive U.S. Phase 2 safety and efficacy data for opaganib, a leading novel, oral, dual-mechanism drug candidate for moderate-to-severe COVID-19, presented at the World Microbe Forum Opaganib was associated w...
Full "IntellAsia: Resources" article
|
|